Ipsen acquiert Epizyme et étend son portefeuille en Oncologie | Business Wire
PRESS RELEASE
ESMO 2021: Cabometyx® demonstrates sustained 78% reduction in risk of disease progression or death in people living with uncom-
PRESS RELEASE
PRESS RELEASE Ipsen announces new data to be presented at ASCO in line with its continued commitment to Oncology research
Ipsen annonce les résultats de l'étude de Phase III RESILIENT évaluant Onivyde® comme monothérapie de deuxième ligne dans le cancer du poumon à petites cellules | Business Wire
News articles listing - Ipsen
Press Releases - Ipsen UK
Press Releases - Ipsen UK
PRESS RELEASE
The FDA approves Somatuline® Depot (lanreotide) Injection Extended Dosing Interval as part of Ipsen's Prior Approval Suppleme
Ipsen intègre un nouveau programme à son portefeuille R&D de produits d'oncologie en phase pré-clinique grâce à une collaboration mondiale exclusive avec Accent Therapeutics, ciblant la protéine modificatrice d'ARN METTL3 | Business
Press Releases - Ipsen
Ipsen (@IpsenGroup) / Twitter
PRESS RELEASE
AGV Discovery Press Release French - FINAL
Press Releases - Ipsen
ASCO 2022: New Cabometyx® data show encouraging results in monotherapy and in combination across different tumor types includin
PRESS RELEASE Ipsen announces acceptance of filings for Somatuline in the treatment of GEP-NETs in the US with priority review a
Press Releases - Ipsen UK
Philippe Lopes-Fernandes on LinkedIn: Ipsen to acquire Epizyme, expanding oncology portfolio
News articles listing - Ipsen
Merrimack Provides Ipsen Report of Results From Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer
